OBL astigmatism could require additional correction

Article

Correcting pre-existing astigmatism could be necessary for achieving excellent visual outcomes in eyes with oblique (OBL) astigmatism.

Correcting pre-existing astigmatism could be necessary for achieving excellent visual outcomes in eyes with oblique (OBL) astigmatism.

A team headed by Dr Hidenaga Kobashi, Department of Ophthalmology, University of Kitasato School of MedicineKanagawa, Japan, conducted an investigational simulation on 38 healthy participants with no ophthalmic complaints apart from refractive errors.

Cycloplegic refraction was fully corrected in all volunteers with a 3.0 mm artificial pupil. With-the-rule (WTR), against-the-rule (ATR), and oblique (OBL) astigmatism of 1.0 D, 2.0 D and 3.0 D were created using trial lenses in all participants.

Trial lenses under cycloplegia enforced distance visual acuity and visual performance with uncorrected astigmatism. The Minnesota Low Vision Reading Test acuity charts were used to assess maximum reading speed and reading acuity was used to determine reading performance.

Axis orientation at each dioptre of astigmatism significantly affected distance visual acuity, reading acuity and maximum reading speed with uncorrected astigmatism. Significantly better values were identified in eyes with WTR or ATR astigmatism in all parameters, compared to eyes with OBL astigmatism.

The abstract can be found in the Journal of Cataract and Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.